Summary
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
History
Nektar Therapeutics was founded in 1990 with a mission to transform the lives of patients. Initial focus areas included delivery of therapeutic proteins to treat cancer and inflammation through the use of polymeric nanotechnology. Over the years, Nektar has advanced a wide range of small molecule, biological, biological-enhanced and candidate biosimilar programs.
Mission
Nektar Therapeutics seeks to identify, develop and commercialize innovative therapies that result in improved patient outcomes.
Vision
Our vision is to develop life-changing therapies that make a real difference for patients, payers, providers and society.
Key Team
Mr. John P. Northcott (Strategic Consulting Advisor)
Ms. Jillian B. Thomsen (Chief Financial Officer)
Mr. Robert Bacci (Sr. VP of HR & Facilities Operations)
Ms. Jennifer Ruddock (Chief Bus. Officer)
Dr. Mary Tagliaferri L.Ac., M.D. (Chief Devel. Officer)
Dr. Brian L. Kotzin M.D. (Chief Medical Officer)
Dr. Kevin Brodbeck Ph.D. (Sr. VP of Technical Operations)
Recognition and Awards
Nektar Therapeutics has won numerous awards, including the 4th Annual PharmaVOICE 100 Most Inspiring People in Life Sciences Award and several Forbes Healthcare Awards.
References
United States 